Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1368 ARTÍCULOS , VIENDO DEL 781 AL 795

Cognitive Improvement with Glutathione Supplement in Alzheimer's Disease: A Way Forward

Mandal PK, Shukla D, Tripathi M, Ersland L.

J Alzheimers Dis. 2019;68(2):531-535. doi: 10.3233/JAD-181054.

Is Alzheimer's Disease Risk Modifiable?

Serrano-Pozo A, Growdon JH.

J Alzheimers Dis. 2019;67(3):795-819. doi: 10.3233/JAD181028.

Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer's Disease

Minakawa EN, Wada K, Nagai Y.

Int J Mol Sci. 2019 Feb 13;20(4):803. doi: 10.3390/ijms20040803.

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics

Varatharajah Y, Ramanan VK, Iyer R, Vemuri P; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Feb 19;9(1):2235. doi: 10.1038/s41598-019-38793-3.

Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review

De Roeck EE, De Deyn PP, Dierckx E, Engelborghs S.

Alzheimers Res Ther. 2019 Feb 28;11(1):21. doi: 10.1186/s13195-019-0474-3.

[Research Advances in Interventions on Subjective Cognitive Decline]

Zhou P, Yan CQ, Wang LQ, Zhang S, Sun N, Hou YQ, Shi GX, Liu CZ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Feb 28;41(1):124-128. doi: 10.3881/j.issn.1000-503X.10829.

Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals

Müller S, Herde L, Preische O, Zeller A, Heymann P, Robens S, Elbing U, Laske C.

Sci Rep. 2019 Mar 5;9(1):3543. doi: 10.1038/s41598-019-40010-0.

Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease

Gul A, Bakht J, Mehmood F.

J Chin Med Assoc. 2019 Jan;82(1):40-43. doi: 10.1016/j.jcma.2018.07.004.

Novelty processing and memory impairment in Alzheimer's disease: A review

Bastin C, Delhaye E, Moulin C, Barbeau EJ.

Neurosci Biobehav Rev. 2019 May;100:237-249. doi: 10.1016/j.neubiorev.2019.02.021. Epub 2019 Mar 7.

Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes

Fiore V, De Rosa A, Falasca P, Marci M, Guastamacchia E, Licchelli B, Giagulli VA, De Pergola G, Poggi A, Triggiani V.

Endocr Metab Immune Disord Drug Targets. 2019;19(5):571-579. doi: 10.2174/1871530319666190311141855.

Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer's Disease

Brandt J, Buchholz A, Henry-Barron B, Vizthum D, Avramopoulos D, Cervenka MC.

J Alzheimers Dis. 2019;68(3):969-981. doi: 10.3233/JAD-180995.

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study

Tsuno N, Mori T, Ishikawa I, Bando N, Park H, Matsumoto Y, Mori I, Tanaka M, Hirano T, Nakamura Y.

Geriatr Gerontol Int. 2019 Jul;19(7):571-576. doi: 10.1111/ggi.13644. Epub 2019 Mar 12.

The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk

Fan J, Tao W, Li X, Li H, Zhang J, Wei D, Chen Y, Zhang Z.

Int J Mol Sci. 2019 Mar 7;20(5):1177. doi: 10.3390/ijms20051177.

Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine

Eid A, Mhatre I, Richardson JR.

Pharmacol Ther. 2019 Jul;199:173-187. doi: 10.1016/j.pharmthera.2019.03.005. Epub 2019 Mar 12.

Editorial: Alzheimer's Disease, aged-related dementias and the search for effective therapeutics

Trist DG.

Curr Opin Pharmacol. 2019 Feb;44:61. doi: 10.1016/j.coph.2019.01.005. Epub 2019 Mar 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias